초록 ▼

This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associate

This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.

대표청구항 ▼

1. A method for treating a patient having tumor cells that express a Her2/neu antigen, the method comprising, administering to the patient in any order an immunotherapy consisting of: (a) a therapeutically effective amount of trastuzumab; and(b) a therapeutically effective amount of a peptide vaccin

1. A method for treating a patient having tumor cells that express a Her2/neu antigen, the method comprising, administering to the patient in any order an immunotherapy consisting of: (a) a therapeutically effective amount of trastuzumab; and(b) a therapeutically effective amount of a peptide vaccine comprising a Her2/neu peptide antigen that consists of the amino acid sequence of SEQ ID NO: 17 (GP2=IISAVVGIL) or SEQ ID NO: 18 (GP2′=IVSAVVGIL), as the sole peptide antigen in the vaccine. 2. The method of claim 1, wherein the Her2/neu peptide antigen is administered before, after or at the same time as administration of the trastuzumab. 3. The method of claim 1, wherein the patient is a breast cancer patient. 4. The method of claim 1, wherein the Her2/neu peptide antigen consists of the amino acid sequence of SEQ ID NO: 17. 5. The method of claim 1, wherein the Her2/neu peptide antigen consists of the amino acid sequence of SEQ ID NO: 18. 6. The method of claim 1, wherein the Her2/neu peptide antigen is administered after the trastuzumab. 7. The method of claim 4, wherein the patient is a breast cancer patient. 8. The method of claim 5, wherein the patient is a breast cancer patient. 9. The method of claim 7, wherein the Her2/neu peptide antigen is administered after the trastuzumab. 10. The method of claim 8, wherein the Her2/neu peptide antigen is administered after the trastuzumab.